Loading…
Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety
Summary— The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18–30 years) with anxiety‐traits, selected on the criteria of Cattell's anxiety scale supported by two personality in...
Saved in:
Published in: | Fundamental & clinical pharmacology 1998-01, Vol.12 (4), p.463-467 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03 |
---|---|
cites | cdi_FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03 |
container_end_page | 467 |
container_issue | 4 |
container_start_page | 463 |
container_title | Fundamental & clinical pharmacology |
container_volume | 12 |
creator | Schuck, S Allain, H Gandon, J-M Patat, A Millet, V Le Coz, F |
description | Summary— The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18–30 years) with anxiety‐traits, selected on the criteria of Cattell's anxiety scale supported by two personality inventory (Eysenck's, MMPI). A double‐blind, placebo study design was chosen. The main assessment criteria were based on the go/no‐go test (Logan's procedure), slow response rate (SRR) and a task of forced or unforced decision (use of the CFF). Attentional processes and declarative memory were analyzed as secondary criteria. None of the three dosages modified inhibition or acting‐out. Sustained attention was reduced with 1.5 mg and 6 mg, as was memory performance with 3 and 6 mg, 3.5 h after drug administration. In contradistinction with studies carried out in healthy volunteers or with other benzodiazepine compounds, bromazepam at single low dosages does not modify inhibition capacity in these subjects with traits of anxiety, in this particular procedure. |
doi_str_mv | 10.1111/j.1472-8206.1998.tb00973.x |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73864584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73864584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03</originalsourceid><addsrcrecordid>eNqVkF2L1DAYhYMo67j6E4Qg4l1rPtom8UKQYXd2cVARxcuQ5sPN2C-T1pn6602ZMvfmJoec5z1vOAC8wijH6bw95LhgJOMEVTkWgudjjZBgND89ApuL9RhsEKtYRgXHT8GzGA8IYYZwdQWuBMOJwxvQ3Dhn9Qh7B-vQt-qvHVQL_9gQpwiHRmlb97DvoO8efO1Hn6TqDDyqpLufUKtBaT_OyYdzP6WXY9_aDh79-ADHkKi4RKvu5O04PwdPnGqifbHe1-D77c237V22_7y7337YZ7rgnGaEEMsNsajCtWEcG2GNqEuiEdW1oQYpQbkzrnDMUoNFYUmBKRWOMu60QvQavDnnDqH_Pdk4ytZHbZtGdbafomSUV0XJiwS-O4M69DEG6-QQfKvCLDGSS9XyIJc-5dKnXKqWa9XylIZfrlumurXmMrp2m_zXq6-iVo0LqtM-XjBCy5KTKmHvz9jRN3b-jw_I2-2XJFJAdg7wcbSnS4AKv2TFKCvlj087-ZF83RPGdhLTf_I9q_I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73864584</pqid></control><display><type>article</type><title>Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Schuck, S ; Allain, H ; Gandon, J-M ; Patat, A ; Millet, V ; Le Coz, F</creator><creatorcontrib>Schuck, S ; Allain, H ; Gandon, J-M ; Patat, A ; Millet, V ; Le Coz, F</creatorcontrib><description>Summary— The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18–30 years) with anxiety‐traits, selected on the criteria of Cattell's anxiety scale supported by two personality inventory (Eysenck's, MMPI). A double‐blind, placebo study design was chosen. The main assessment criteria were based on the go/no‐go test (Logan's procedure), slow response rate (SRR) and a task of forced or unforced decision (use of the CFF). Attentional processes and declarative memory were analyzed as secondary criteria. None of the three dosages modified inhibition or acting‐out. Sustained attention was reduced with 1.5 mg and 6 mg, as was memory performance with 3 and 6 mg, 3.5 h after drug administration. In contradistinction with studies carried out in healthy volunteers or with other benzodiazepine compounds, bromazepam at single low dosages does not modify inhibition capacity in these subjects with traits of anxiety, in this particular procedure.</description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><identifier>DOI: 10.1111/j.1472-8206.1998.tb00973.x</identifier><identifier>PMID: 9711471</identifier><identifier>CODEN: FCPHEZ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Oral ; Adolescent ; Adult ; Anti-Anxiety Agents - pharmacology ; Anti-Anxiety Agents - therapeutic use ; anxiety ; Anxiety - drug therapy ; Attention - drug effects ; benzodiazepine ; Biological and medical sciences ; bromazepam ; Bromazepam - pharmacology ; Bromazepam - therapeutic use ; cognition ; Double-Blind Method ; Female ; Humans ; inhibition ; Medical sciences ; memory ; Memory - drug effects ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychometrics ; Psychopharmacology</subject><ispartof>Fundamental & clinical pharmacology, 1998-01, Vol.12 (4), p.463-467</ispartof><rights>1998 Société Française de Pharmacologie et de Thérapeutique</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03</citedby><cites>FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2355826$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9711471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schuck, S</creatorcontrib><creatorcontrib>Allain, H</creatorcontrib><creatorcontrib>Gandon, J-M</creatorcontrib><creatorcontrib>Patat, A</creatorcontrib><creatorcontrib>Millet, V</creatorcontrib><creatorcontrib>Le Coz, F</creatorcontrib><title>Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety</title><title>Fundamental & clinical pharmacology</title><addtitle>Fundam Clin Pharmacol</addtitle><description>Summary— The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18–30 years) with anxiety‐traits, selected on the criteria of Cattell's anxiety scale supported by two personality inventory (Eysenck's, MMPI). A double‐blind, placebo study design was chosen. The main assessment criteria were based on the go/no‐go test (Logan's procedure), slow response rate (SRR) and a task of forced or unforced decision (use of the CFF). Attentional processes and declarative memory were analyzed as secondary criteria. None of the three dosages modified inhibition or acting‐out. Sustained attention was reduced with 1.5 mg and 6 mg, as was memory performance with 3 and 6 mg, 3.5 h after drug administration. In contradistinction with studies carried out in healthy volunteers or with other benzodiazepine compounds, bromazepam at single low dosages does not modify inhibition capacity in these subjects with traits of anxiety, in this particular procedure.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-Anxiety Agents - pharmacology</subject><subject>Anti-Anxiety Agents - therapeutic use</subject><subject>anxiety</subject><subject>Anxiety - drug therapy</subject><subject>Attention - drug effects</subject><subject>benzodiazepine</subject><subject>Biological and medical sciences</subject><subject>bromazepam</subject><subject>Bromazepam - pharmacology</subject><subject>Bromazepam - therapeutic use</subject><subject>cognition</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>inhibition</subject><subject>Medical sciences</subject><subject>memory</subject><subject>Memory - drug effects</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychometrics</subject><subject>Psychopharmacology</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqVkF2L1DAYhYMo67j6E4Qg4l1rPtom8UKQYXd2cVARxcuQ5sPN2C-T1pn6602ZMvfmJoec5z1vOAC8wijH6bw95LhgJOMEVTkWgudjjZBgND89ApuL9RhsEKtYRgXHT8GzGA8IYYZwdQWuBMOJwxvQ3Dhn9Qh7B-vQt-qvHVQL_9gQpwiHRmlb97DvoO8efO1Hn6TqDDyqpLufUKtBaT_OyYdzP6WXY9_aDh79-ADHkKi4RKvu5O04PwdPnGqifbHe1-D77c237V22_7y7337YZ7rgnGaEEMsNsajCtWEcG2GNqEuiEdW1oQYpQbkzrnDMUoNFYUmBKRWOMu60QvQavDnnDqH_Pdk4ytZHbZtGdbafomSUV0XJiwS-O4M69DEG6-QQfKvCLDGSS9XyIJc-5dKnXKqWa9XylIZfrlumurXmMrp2m_zXq6-iVo0LqtM-XjBCy5KTKmHvz9jRN3b-jw_I2-2XJFJAdg7wcbSnS4AKv2TFKCvlj087-ZF83RPGdhLTf_I9q_I</recordid><startdate>19980101</startdate><enddate>19980101</enddate><creator>Schuck, S</creator><creator>Allain, H</creator><creator>Gandon, J-M</creator><creator>Patat, A</creator><creator>Millet, V</creator><creator>Le Coz, F</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980101</creationdate><title>Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety</title><author>Schuck, S ; Allain, H ; Gandon, J-M ; Patat, A ; Millet, V ; Le Coz, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-Anxiety Agents - pharmacology</topic><topic>Anti-Anxiety Agents - therapeutic use</topic><topic>anxiety</topic><topic>Anxiety - drug therapy</topic><topic>Attention - drug effects</topic><topic>benzodiazepine</topic><topic>Biological and medical sciences</topic><topic>bromazepam</topic><topic>Bromazepam - pharmacology</topic><topic>Bromazepam - therapeutic use</topic><topic>cognition</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>inhibition</topic><topic>Medical sciences</topic><topic>memory</topic><topic>Memory - drug effects</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychometrics</topic><topic>Psychopharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schuck, S</creatorcontrib><creatorcontrib>Allain, H</creatorcontrib><creatorcontrib>Gandon, J-M</creatorcontrib><creatorcontrib>Patat, A</creatorcontrib><creatorcontrib>Millet, V</creatorcontrib><creatorcontrib>Le Coz, F</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fundamental & clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schuck, S</au><au>Allain, H</au><au>Gandon, J-M</au><au>Patat, A</au><au>Millet, V</au><au>Le Coz, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety</atitle><jtitle>Fundamental & clinical pharmacology</jtitle><addtitle>Fundam Clin Pharmacol</addtitle><date>1998-01-01</date><risdate>1998</risdate><volume>12</volume><issue>4</issue><spage>463</spage><epage>467</epage><pages>463-467</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><coden>FCPHEZ</coden><abstract>Summary— The effect of 3 dosages of bromazepam administered as single oral doses (1.5, 3 and 6 mg) on anxious inhibition phenomena was studied in a population of 16 young women (18–30 years) with anxiety‐traits, selected on the criteria of Cattell's anxiety scale supported by two personality inventory (Eysenck's, MMPI). A double‐blind, placebo study design was chosen. The main assessment criteria were based on the go/no‐go test (Logan's procedure), slow response rate (SRR) and a task of forced or unforced decision (use of the CFF). Attentional processes and declarative memory were analyzed as secondary criteria. None of the three dosages modified inhibition or acting‐out. Sustained attention was reduced with 1.5 mg and 6 mg, as was memory performance with 3 and 6 mg, 3.5 h after drug administration. In contradistinction with studies carried out in healthy volunteers or with other benzodiazepine compounds, bromazepam at single low dosages does not modify inhibition capacity in these subjects with traits of anxiety, in this particular procedure.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>9711471</pmid><doi>10.1111/j.1472-8206.1998.tb00973.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0767-3981 |
ispartof | Fundamental & clinical pharmacology, 1998-01, Vol.12 (4), p.463-467 |
issn | 0767-3981 1472-8206 |
language | eng |
recordid | cdi_proquest_miscellaneous_73864584 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Administration, Oral Adolescent Adult Anti-Anxiety Agents - pharmacology Anti-Anxiety Agents - therapeutic use anxiety Anxiety - drug therapy Attention - drug effects benzodiazepine Biological and medical sciences bromazepam Bromazepam - pharmacology Bromazepam - therapeutic use cognition Double-Blind Method Female Humans inhibition Medical sciences memory Memory - drug effects Neuropharmacology Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychometrics Psychopharmacology |
title | Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A36%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20bromazepam%20versus%20placebo%20on%20inhibition%20and%20waiting%20capacity%20in%20young%20women%20with%20traits%20of%20anxiety&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Schuck,%20S&rft.date=1998-01-01&rft.volume=12&rft.issue=4&rft.spage=463&rft.epage=467&rft.pages=463-467&rft.issn=0767-3981&rft.eissn=1472-8206&rft.coden=FCPHEZ&rft_id=info:doi/10.1111/j.1472-8206.1998.tb00973.x&rft_dat=%3Cproquest_cross%3E73864584%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4883-222e8d2e061bd781d9ed9b52c03cbd3d0a938fdf4f7e3d194e241339f378fca03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73864584&rft_id=info:pmid/9711471&rfr_iscdi=true |